Safety of Anti-Reelin Therapeutic Approaches for Chronic Inflammatory Diseases
Cells · 27.03.2024 · 13 (7) · 583
DOI: 10.3390/cells13070583 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 27.03.2024. Verfasst von Laurent Calvier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Reelin Protein, Encephalomyelitis, Autoimmune, Experimental, Anti-Inflammatory Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NINDS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Reelin, a large extracellular glycoprotein, plays critical roles in neuronal development and synaptic plasticity in the central nervous system (CNS). Recent studies have revealed non-neuronal functions of plasma Reelin in inflammation by promoting endothelial–leukocyte adhesion through its canonical pathway in endothelial cells (via ApoER2 acting on NF-κB), as well as in vascular tone regulation and thrombosis. In this study, we have investigated the safety and efficacy of selectively depleting plasma Reelin as a potential therapeutic strategy for chronic inflammatory diseases. We found that Reelin expression remains stable throughout adulthood and that peripheral anti-Reelin antibody treatment with CR-50 efficiently depletes plasma Reelin without affecting its levels or functionality within the CNS. Notably, this approach preserves essential neuronal functions and synaptic plasticity. Furthermore, in mice induced with experimental autoimmune encephalomyelitis (EAE), selective modulation of endothelial responses by anti-Reelin antibodies reduces pathological leukocyte infiltration without completely abolishing diapedesis. Finally, long-term Reelin depletion under metabolic stress induced by a Western diet did not negatively impact the heart, kidney, or liver, suggesting a favorable safety profile. These findings underscore the promising role of peripheral anti-Reelin therapeutic strategies for autoimmune diseases and conditions where endothelial function is compromised, offering a novel approach that may avoid the immunosuppressive side effects associated with conventional anti-inflammatory therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Genetics, University of Texas (UT) Southwestern Medical Center, Dallas, TX 75390, USA.
- Center for Translational Neurodegeneration Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Reelin Therapeutics Inc., La Jolla, CA 92130, USA.
- Department of Neuroscience, UT Southwestern Medical Center, Dallas, TX 75390, USA.
- Department of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
ORCID-Profile: Laurent Calvier, Austin T Marckx, Murat Durakoglugil
Förderung
- NIDDK NIH HHS
- NINDS NIH HHS
- NHLBI NIH HHS
- NIA NIH HHS
- DFG
- NHLBI
- NIA
- NINDS
Zitieren
APA
Calvier, L., Alexander, A., Marckx, A. T., Kounnas, M. Z., Durakoglugil, M., & Herz, J. (2024). Safety of Anti-Reelin Therapeutic Approaches for Chronic Inflammatory Diseases. Cells, 13(7), 583. https://doi.org/10.3390/cells13070583
Vancouver
Calvier L, Alexander A, Marckx AT, Kounnas MZ, Durakoglugil M, Herz J. Safety of Anti-Reelin Therapeutic Approaches for Chronic Inflammatory Diseases. Cells. 2024;13(7):583. doi:10.3390/cells13070583
BibTeX
@article{Calvier2024,
author = {Calvier, Laurent and Alexander, Anna and Marckx, Austin T and Kounnas, Maria Z and Durakoglugil, Murat and Herz, Joachim},
title = {Safety of Anti-Reelin Therapeutic Approaches for Chronic Inflammatory Diseases},
journal = {Cells},
year = {2024},
volume = {13},
number = {7},
pages = {583},
doi = {10.3390/cells13070583}
}
EUVIMED